Perspective Therapeutics Dirección

Dirección controles de criterios 1/4

El CEO de Perspective Therapeutics' es Thijs Spoor , nombrado en Feb 2023, tiene una permanencia de 1.5 años. compensación anual total es $1.46M, compuesta por 34.7% salario y 65.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.031% de las acciones de la empresa, por valor de €284.33K. La antigüedad media del equipo directivo y de la junta directiva es de 1.5 años y 1.5 años, respectivamente.

Información clave

Thijs Spoor

Chief Executive Officer (CEO)

US$1.5m

Compensación total

Porcentaje del salario del CEO	34.7%
Permanencia del CEO	1.7yrs
Participación del CEO	0.03%
Permanencia media de la dirección	1.6yrs
Promedio de permanencia en la Junta Directiva	1.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Thijs Spoor en comparación con los beneficios de Perspective Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$52m
Mar 31 2024	n/a	n/a	-US$50m
Dec 31 2023	US$1m	US$506k	-US$37m

Compensación vs. Mercado: La compensación total ($USD1.46M) de Thijs está en línea con el promedio de empresas de tamaño similar en el mercado German ($USD1.46M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Thijs con los resultados de la empresa.

CEO

Thijs Spoor (52 yo)

1.7yrs

Permanencia

US$1,458,996

Compensación

Mr. Johan M. Spoor, also known as Thijs, is Chief Executive Officer and Director at Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) since February 05, 2023. He founded AzurRx BioPharma, Inc...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Johan Spoor	CEO & Director	1.7yrs	US$1.46m	0.031% $ 249.8k
Jonathan Hunt	CFO and Principal Financial & Accounting Officer	5.8yrs	US$1.17m	0.053% $ 433.0k
Markus Puhlmann	Chief Medical Officer	1.7yrs	US$900.09k	0.20% $ 1.7m
Shane Cobb	Executive Vice President of Operations	1.2yrs	sin datos	sin datos
Michael Schultz	Chief Science Officer	no data	sin datos	2.2% $ 17.9m
Andrew Bright	Executive Vice President of Brachytherapy	1.5yrs	sin datos	sin datos
Amos Hedt	Chief Business Strategy Officer	no data	sin datos	sin datos
Frances Johnson	Chief Innovation Officer	no data	sin datos	2.2% $ 17.9m
David Hauser	Senior Vice President of Clinical Operations	no data	sin datos	sin datos
Steve Keefe	Senior Vice President of Clinical Development	less than a year	sin datos	sin datos

1.6yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AAJ0 no se considera experimentado ( 1.5 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Johan Spoor	CEO & Director	1.7yrs	US$1.46m	0.031% $ 249.8k
Robert Williamson	Independent Director	1.7yrs	US$320.06k	0.063% $ 514.5k
Frank Morich	Independent Director	1.7yrs	US$320.06k	sin datos
Heidi Henson	Independent Director	1.3yrs	US$390.70k	sin datos
Lori Holmes-Woods	Chairperson of the Board	6.3yrs	US$671.73k	0.24% $ 2.0m

1.7yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de AAJ0 no se considera experimentada (1.5 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Perspective Therapeutics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

High number of new and inexperienced directors

CEO & Director recently bought €109k worth of stock

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Chief Medical Officer recently bought €128k worth of stock

Chief Medical Officer recently bought €172k worth of stock

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

Recent updates

High number of new and inexperienced directors

Perspective Therapeutics Grants Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $49.868808 million.

Perspective Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

CEO & Director recently bought €109k worth of stock

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.998535 million.

First quarter 2024 earnings released: US$0.024 loss per share (vs US$0.002 loss in 1Q 2023)

Perspective Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Profitability

No longer forecast to breakeven

New minor risk - Revenue size

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.10 loss in FY 2022)

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc.

Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors

Perspective Therapeutics, Inc. (NYSEAM:CATX) completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.

Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform

Chief Medical Officer recently bought €128k worth of stock

Forecast to breakeven in 2026

Perspective Therapeutics, Inc. announced that it has received $20.846671 million in funding from Lantheus Alpha Therapy, LLC

Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in funding

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering.

Chief Medical Officer recently bought €172k worth of stock

Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in Germany

Perspective Therapeutics, Inc. Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

New major risk - Financial position

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.029 loss in 3Q 2022)

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2A Study of [(212)Pb VMT-a-Net for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces Two Upcoming Investigator-Initiated Trials

Perspective Therapeutics, Inc. Announces Presentation of Positive Early Clinical Data for VMT-a-NET at 36th Annual Congress of European Association of Nuclear Medicine

Perspective Therapeutics, Inc. Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

New major risk - Financial position

Second quarter 2023 earnings released: US$0.04 loss per share (vs US$0.015 loss in 2Q 2022)

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

Perspective Therapeutics, Inc. Announces Termination of Jennifer Streeter as Chief Operating Officer

Less than half of directors are independent

Perspective Therapeutics, Inc.'s Cesium-131 Features at the American Brachytherapy Society's Annual Conference

Perspective Therapeutics, Inc. Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Less than half of directors are independent

Perspective Therapeutics, Inc. Announces Changes to the Board of Directors

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.009 loss in 1Q 2022)

Second quarter 2023 earnings released: US$0.02 loss per share (vs US$0.011 loss in 2Q 2022)

Isoray, Inc. Announces Termination of William Cavanagh III as Chief Research and Development Officer

Isoray, Inc. Announces Executive Changes

Isoray, Inc., Annual General Meeting, Jan 12, 2023

First quarter 2023 earnings released: US$0.029 loss per share (vs US$0.016 loss in 1Q 2022)

Insufficient new directors

Isoray, Inc. to Report Q1, 2023 Results on Nov 10, 2022

Full year 2022 earnings released: US$0.051 loss per share (vs US$0.033 loss in FY 2021)

Isoray, Inc. (NYSEAM:ISR) entered into an Agreement and Plan of Merger to acquire Viewpoint Molecular Targeting, Inc.

Isoray, Inc. to Report Q4, 2022 Results on Sep 28, 2022

Third quarter 2022 earnings released: US$0.009 loss per share (vs US$0.006 loss in 3Q 2021)

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad